Nuvalent Executive Compensation (FY25)
NUVL · Executive and director compensation, fiscal 2025 only
The paid brief on Nuvalent
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 18, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
194 figures on this page: 191 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
More on Nuvalent
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Nuvalent's chief executive and what were they paid?
James Porter, President and Chief Executive Officer, received $11,393,602 in total compensation for fiscal 2025.
What was Nuvalent's say-on-pay result?
Shareholders supported the say-on-pay proposal with 97.5% of votes cast for or against in favor at the meeting held June 16, 2026 for fiscal 2025.
Which companies are in Nuvalent's peer group?
The disclosed peer group names Arcellx, Inc., Arrowhead Pharmaceuticals, Inc., Avidity Biosciences, Inc., CRISPR Therapeutics AG and Cytokinetics, Incorporated, among others.
What is Nuvalent's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 21:1, against median employee compensation of $540,474.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
James Porter President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christopher Turner Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Alexandra Balcom Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Darlene Noci Chief Development Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Deborah Miller Chief Legal Officer and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Alexandra Balcom | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Alexandra Balcom | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christopher D. Turner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Christopher D. Turner | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Darlene Noci | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Darlene Noci | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Deborah Miller | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Deborah Miller | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| James R. Porter | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| James R. Porter | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Christopher Turner | Option | ◇ | — | ◇ | 1/4/2032 |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 8/1/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/6/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| Option | ◇ | — | ◇ | 1/4/2032 | |
| Option | ◇ | — | ◇ | 1/6/2035 | |
| Deborah Miller | Option | ◇ | — | ◇ | 1/6/2035 |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2032 | |
| Option | ◇ | — | ◇ | 1/6/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Alexandra Balcom | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2032 | |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| Option | ◇ | — | ◇ | 1/6/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/4/2032 | |
| Option | ◇ | — | ◇ | 1/6/2035 | |
| Option | ◇ | — | ◇ | 8/1/2032 | |
| James Porter | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 1/5/2034 | |
| Option | ◇ | — | ◇ | 1/4/2032 | |
| Option | ◇ | — | ◇ | 1/6/2033 | |
| Option | ◇ | — | ◇ | 1/6/2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Matthew Shair, Ph.D | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Christy Oliger | ◇ | ◇ | ◇ | — | — | — | ◇ |
Ron Squarer | ◇ | ◇ | ◇ | — | — | — | ◇ |
Anna Protopapas | ◇ | ◇ | ◇ | — | — | — | ◇ |
Sapna Srivastava, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Cameron A. Wheeler, Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Michael L. Meyers, M.D., Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Grant C. Bogle | ◇ | ◇ | ◇ | — | — | — | ◇ |
Joseph Pearlberg, M.D., Ph.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Gary Gilliland, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Emily Drabant Conley, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Andrew A. F. Hack, M.D., Ph.D | ◇ | — | — | — | — | — | ◇ |
James R. Porter, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board equity retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Arcellx, Inc. ACLX
- Arrowhead Pharmaceuticals, Inc. ARWR
- Avidity Biosciences, Inc. RNAM
- CRISPR Therapeutics AG CRSP
- Cytokinetics, Incorporated CYTK
- Denali Therapeutics Inc. DNLI
- Immunovant, Inc. IMVT
- Madrigal Pharmaceuticals, Inc. MDGL
- Revolution Medicines, Inc. RVMD
- Summit Therapeutics Inc. SMMT
- Vaxcyte, Inc. PCVX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 16, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 12, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Nuvalent disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Nuvalent sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
194 figures on this page: 191 cited to the filing that reported them, 3 calculated from figures it prints.
191 cited to the filing
3 calculated from the filing
Documents cited
- 0001861560-26-000023Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001861560-26-000013CEO Pay Ratio · Director Compensation table · Grants of Plan-Based Awards · OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKH · and 2 more sections
- 0000950170-25-088542Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-073632Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Nuvalent executive compensation, FY2025.” https://intel.velarion.ai/comp/NUVL (accessed 2026).
Short form: data: Velarion
The paid brief for Nuvalent
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Nuvalent and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Nuvalent discloses
The companies named in NUVL's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}